CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis

Bibliografski detalji
Glavni autori:	Lutgens, E, Mulder, WJM, Monaco, C
Daljnji autori:	CHECKPOINT ATHERO consortium
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2023

Slični predmeti

Risk factors in coronary atherosclerosis athero-inflammation: the meeting point
od: Altman Raul
Izdano: (2003-07-01)

Immune checkpoints as therapeutic targets in autoimmunity
od: Paluch, C, i dr.
Izdano: (2018)

Acute coronary disease Athero-Inflammation: Therapeutic approach
od: Altman Raul
Izdano: (2003-06-01)

The ATHERO-AF Study
od: Michael D. Ezekowitz, MBChB, DPhil, i dr.
Izdano: (2024-08-01)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
od: Christopher Paluch, i dr.
Izdano: (2018-10-01)

Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis
od: Sarah Colijn, i dr.
Izdano: (2020-01-01)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
od: Pal Maurovich-Horvat, i dr.
Izdano: (2023-07-01)

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
od: Esther Lutgens, i dr.
Izdano: (2022-09-01)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
od: Florian Huemer, i dr.
Izdano: (2021-01-01)

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
od: Esther Lutgens, i dr.
Izdano: (2020-05-01)

Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
od: Vafa Meftahpour, i dr.
Izdano: (2022-01-01)

Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy
od: Jinyun Yuan, i dr.
Izdano: (2021-03-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
od: Naoki Hama, i dr.
Izdano: (2022-01-01)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
od: Akintunde Akinleye, i dr.
Izdano: (2019-09-01)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
od: Naoki Hama, i dr.
Izdano: (2020-10-01)

From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
od: Yibin Zhou, i dr.
Izdano: (2024-02-01)

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
od: Stephanie C. Pitts, i dr.
Izdano: (2024-05-01)

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine
od: Pournima Kadam, i dr.
Izdano: (2020-11-01)

Immune checkpoint molecules in prevention and development of asthma
od: Zahra Kanannejad, i dr.
Izdano: (2023-02-01)

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
od: Esther Lutgens, i dr.
Izdano: (2021-06-01)

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
od: Jared M. Newton, i dr.
Izdano: (2019-08-01)

The Alcohol–High-Density Lipoprotein Athero-Protective Axis
od: Corina Rosales, i dr.
Izdano: (2020-07-01)

Immune checkpoint analysis in ear cancer
od: M. Klein, i dr.
Izdano: (2023-11-01)

Biomarkers for immune checkpoint blockers
od: Kirsty Wienand, i dr.
Izdano: (2018-06-01)

Immune Checkpoints in Viral Infections
od: Huiming Cai, i dr.
Izdano: (2020-09-01)

Immune checkpoint blockade in HIV
od: Celine Gubser, i dr.
Izdano: (2022-02-01)

Immune Checkpoint Inhibitors and the Heart
od: Diana Larisa Mocan-Hognogi, i dr.
Izdano: (2021-09-01)

Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process
od: E. Anglés-Cano
Izdano: (1997-11-01)

Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors
od: Zafer Gurel, i dr.
Izdano: (2024-10-01)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
od: Magalie Dosset, i dr.
Izdano: (2020-07-01)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
od: Mark P. Chao, i dr.
Izdano: (2020-01-01)

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
od: Xueyin Zhou, i dr.
Izdano: (2022-05-01)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
od: Margaret A. McBride, i dr.
Izdano: (2021-02-01)

Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
od: Yujia Zhai, i dr.
Izdano: (2021-04-01)

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
od: Nicholas Gravbrot, i dr.
Izdano: (2019-10-01)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
od: Alice Mougel, i dr.
Izdano: (2019-03-01)

Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
od: Caroline E. Nunes-Xavier
Izdano: (2024-09-01)

Low HDL-C level is associated with the development of intracranial artery stenosis: analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) study.
od: Yining Qian, i dr.
Izdano: (2013-01-01)

Editorial: The therapeutic inhibition of macrophage checkpoints
od: Alexandre P. A. Theocharides, i dr.
Izdano: (2024-04-01)

CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide.
od: Kuang-Yuh Chyu, i dr.
Izdano: (2012-01-01)